Herceptin Biosimilars Market Size, Share, Trends, Industry Analysis Report: By Application, Dosage, End-Users, Distribution Channel, and Region

Description

List of Tables

The global Herceptin Biosimilars market size is expected to reach USD 21,271.43 Million by 2034, according to a new study by Polaris Market Research. The report "Herceptin Biosimilars Market Size, Share, Trends, Industry Analysis Report: By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, and Others), Dosage, End-Users, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Herceptin biosimilars market encompasses the commercial activities surrounding biosimilar versions of trastuzumab, a recombinant humanized monoclonal antibody initially developed as Herceptin. These biosimilars are biological products that are demonstrated to be highly similar to the reference product in terms of safety, efficacy, and quality. They offer a more cost-effective alternative to the original biologic drug, which is a crucial targeted therapy for HER2-positive breast and gastric cancers. The introduction and increasing adoption of Herceptin biosimilars play a significant role in expanding patient access to these essential treatments while also alleviating the financial burden on healthcare systems globally.

The Herceptin biosimilars market is experiencing substantial growth driven by several key factors. The expiration of patent protection for the originator product in various regions has paved the way for numerous manufacturers to enter the market. This increased competition among biosimilar manufacturers is contributing to price erosion, making trastuzumab therapy more affordable. Furthermore, supportive regulatory frameworks in many countries are streamlining the approval process for biosimilars, encouraging their development and market entry. The rising prevalence of HER2-positive cancers worldwide also fuels a strong and consistent market demand for effective treatment options like trastuzumab biosimilars. The focus on cost containment within healthcare systems globally further incentivizes the uptake of these more economical alternatives, shaping a positive market outlook for the Herceptin biosimilars market.

Herceptin Biosimilars Market Report Highlights:

By application, the breast cancer segment currently holds the largest market share globally due to the high prevalence of HER2-positive breast cancer and the established clinical utility of trastuzumab in its treatment across various stages.
By dosage, the 150mg/single-dose vial segment presently accounts for the largest market share. This is attributed to established prescribing practices, the flexibility in tailoring dosages to individual patient needs, and the minimization of contamination and wastage, making it a preferred format in many healthcare settings.
By end-users, hospitals currently represent the largest end-user segment in the Herceptin biosimilars market. Their dominance stems from their central role in cancer diagnosis and treatment, particularly for intravenous therapies like trastuzumab biosimilars.
By distribution channel, the hospital pharmacy segment currently holds the largest share of the Herceptin biosimilars market. This is because the primary mode of administration for these biosimilars is intravenous infusion under medical supervision, making hospital pharmacies the direct and primary channel for dispensing these medications to patients within their care.
By region, North America and Europe have been early adopters of biosimilars, driven by well-established regulatory pathways and significant healthcare expenditure. The Asia Pacific region is emerging as a high-growth market due to increasing cancer incidence and growing healthcare access.
The prominent participants actively involved in the Herceptin biosimilars market include Biocon Biologics Limited (Biocon Limited), Celltrion Healthcare Co., Ltd. (Celltrion, Inc.), Mylan Pharmaceuticals Inc. (Viatris Inc.), Amgen Inc., Novartis AG (Sandoz International GmbH), Pfizer Inc., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co., Ltd. (Samsung Group), Shanghai Henlius Biotech, Inc., and Innovent Biologics, Inc.

Polaris Market Research has segmented the Herceptin Biosimilars market report based on application, dosage, end users, distribution channel, and region:

By Application Outlook (Revenue-USD Million, 2020-2034)

Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
Others

By Dosage Outlook (Revenue-USD Million, 2020-2034)

150mg/single-dose vial
420mg/multidose vial

By End-Users Outlook (Revenue-USD Million, 2020-2034)

Specialty Clinics
Hospitals
Oncology Centers
Others

By Distribution Channel Outlook (Revenue-USD Million, 2020-2034)

Direct Tender
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

By Regional Outlook (Revenue-USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia-Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia-Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM5647

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Herceptin Biosimilars Market Insights

4.1. Herceptin Biosimilars Market - Market Snapshot
4.2. Herceptin Biosimilars Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Prevalence of HER2-Positive Cancers
  - 4.2.1.2. Cost Containment Pressures in Healthcare Systems
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Physician and Patient Reluctance
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Herceptin Biosimilars Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Herceptin Biosimilars Market, by Application

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
5.3. Breast Cancer
- 5.3.1. Global Herceptin Biosimilars Market, by Breast Cancer, by Region, 2020-2034 (USD Million)
5.4. Colorectal Cancer
- 5.4.1. Global Herceptin Biosimilars Market, by Colorectal Cancer, by Region, 2020-2034 (USD Million)
5.5. Leukemia
- 5.5.1. Global Herceptin Biosimilars Market, by Leukemia, by Region, 2020-2034 (USD Million)
5.6. Lymphoma
- 5.6.1. Global Herceptin Biosimilars Market, by Lymphoma, by Region, 2020-2034 (USD Million)
5.7. Others
- 5.7.1. Global Herceptin Biosimilars Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Herceptin Biosimilars Market, by Dosage

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
6.3. 150mg/single-dose vial
- 6.3.1. Global Herceptin Biosimilars Market, by 150mg/single-dose vial, by Region, 2020-2034 (USD Million)
6.4. 420mg/multidose vial
- 6.4.1. Global Herceptin Biosimilars Market, by 420mg/multidose vial, by Region, 2020-2034 (USD Million)

7. Global Herceptin Biosimilars Market, by End-Users

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
7.3. Specialty Clinics
- 7.3.1. Global Herceptin Biosimilars Market, by Specialty Clinics, by Region, 2020-2034 (USD Million)
7.4. Hospitals
- 7.4.1. Global Herceptin Biosimilars Market, by Hospitals, by Region, 2020-2034 (USD Million)
7.5. Oncology Centers
- 7.5.1. Global Herceptin Biosimilars Market, by Oncology Centers, by Region, 2020-2034 (USD Million)
7.6. Others
- 7.6.1. Global Herceptin Biosimilars Market, by Others, by Region, 2020-2034 (USD Million)

8. Global Herceptin Biosimilars Market, by Distribution Channel

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
8.3. Direct Tender
- 8.3.1. Global Herceptin Biosimilars Market, by Direct Tender, by Region, 2020-2034 (USD Million)
8.4. Hospital Pharmacy
- 8.4.1. Global Herceptin Biosimilars Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Million)
8.5. Retail Pharmacy
- 8.5.1. Global Herceptin Biosimilars Market, by Retail Pharmacy, by Region, 2020-2034 (USD Million)
8.6. Online Pharmacy
- 8.6.1. Global Herceptin Biosimilars Market, by Online Pharmacy, by Region, 2020-2034 (USD Million)
8.7. Others
- 8.7.1. Global Herceptin Biosimilars Market, by Others, by Region, 2020-2034 (USD Million)

9. Global Herceptin Biosimilars Market, by Geography

9.1. Key Findings
9.2. Introduction
- 9.2.1. Herceptin Biosimilars Market Assessment, By Geography, 2020-2034 (USD Million)
9.3. Herceptin Biosimilars Market - North America
- 9.3.1. North America: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
- 9.3.2. North America: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
- 9.3.3. North America: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
- 9.3.4. North America: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.3.5. Herceptin Biosimilars Market - US
  - 9.3.5.1. US: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.3.5.2. US: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.3.5.3. US: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.3.5.4. US: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.3.6. Herceptin Biosimilars Market - Canada
  - 9.3.6.1. Canada: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.3.6.2. Canada: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.3.6.3. Canada: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.3.6.4. Canada: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
9.4. Herceptin Biosimilars Market - Europe
- 9.4.1. Europe: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
- 9.4.2. Europe: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
- 9.4.3. Europe: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
- 9.4.4. Europe: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.5. Herceptin Biosimilars Market - UK
  - 9.4.5.1. UK: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.5.2. UK: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.5.3. UK: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.5.4. UK: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.6. Herceptin Biosimilars Market - France
  - 9.4.6.1. France: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.6.2. France: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.6.3. France: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.6.4. France: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.7. Herceptin Biosimilars Market - Germany
  - 9.4.7.1. Germany: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.7.2. Germany: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.7.3. Germany: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.7.4. Germany: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.8. Herceptin Biosimilars Market - Italy
  - 9.4.8.1. Italy: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.8.2. Italy: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.8.3. Italy: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.8.4. Italy: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.9. Herceptin Biosimilars Market - Spain
  - 9.4.9.1. Spain: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.9.2. Spain: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.9.3. Spain: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.9.4. Spain: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.10. Herceptin Biosimilars Market - Netherlands
  - 9.4.10.1. Netherlands: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.10.2. Netherlands: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.10.3. Netherlands: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.10.4. Netherlands: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.11. Herceptin Biosimilars Market - Russia
  - 9.4.11.1. Russia: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.11.2. Russia: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.11.3. Russia: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.11.4. Russia: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.12. Herceptin Biosimilars Market - Rest of Europe
  - 9.4.12.1. Rest of Europe: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.4.12.2. Rest of Europe: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.4.12.3. Rest of Europe: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.4.12.4. Rest of Europe: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
9.5. Herceptin Biosimilars Market - Asia Pacific
- 9.5.1. Asia Pacific: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
- 9.5.2. Asia Pacific: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
- 9.5.3. Asia Pacific: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
- 9.5.4. Asia Pacific: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.5. Herceptin Biosimilars Market - China
  - 9.5.5.1. China: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.5.2. China: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.5.3. China: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.5.4. China: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.6. Herceptin Biosimilars Market - India
  - 9.5.6.1. India: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.6.2. India: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.6.3. India: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.6.4. India: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.7. Herceptin Biosimilars Market - Malaysia
  - 9.5.7.1. Malaysia: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.7.2. Malaysia: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.7.3. Malaysia: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.7.4. Malaysia: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.8. Herceptin Biosimilars Market - Japan
  - 9.5.8.1. Japan: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.8.2. Japan: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.8.3. Japan: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.8.4. Japan: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.9. Herceptin Biosimilars Market - Indonesia
  - 9.5.9.1. Indonesia: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.9.2. Indonesia: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.9.3. Indonesia: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.9.4. Indonesia: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.10. Herceptin Biosimilars Market - South Korea
  - 9.5.10.1. South Korea: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.10.2. South Korea: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.10.3. South Korea: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.10.4. South Korea: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.11. Herceptin Biosimilars Market - Australia
  - 9.5.11.1. Australia: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.11.2. Australia: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.11.3. Australia: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.11.4. Australia: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.12. Herceptin Biosimilars Market - Rest of Asia Pacific
  - 9.5.12.1. Rest of Asia Pacific: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.5.12.2. Rest of Asia Pacific: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.5.12.3. Rest of Asia Pacific: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.5.12.4. Rest of Asia Pacific: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
9.6. Herceptin Biosimilars Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
- 9.6.2. Middle East & Africa: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
- 9.6.3. Middle East & Africa: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
- 9.6.4. Middle East & Africa: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.5. Herceptin Biosimilars Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.6.5.2. Saudi Arabia: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.6.5.3. Saudi Arabia: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.6.5.4. Saudi Arabia: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.6. Herceptin Biosimilars Market - UAE
  - 9.6.6.1. UAE: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.6.6.2. UAE: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.6.6.3. UAE: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.6.6.4. UAE: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.7. Herceptin Biosimilars Market - Israel
  - 9.6.7.1. Israel: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.6.7.2. Israel: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.6.7.3. Israel: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.6.7.4. Israel: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.8. Herceptin Biosimilars Market - South Africa
  - 9.6.8.1. South Africa: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.6.8.2. South Africa: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.6.8.3. South Africa: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.6.8.4. South Africa: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.9. Herceptin Biosimilars Market - Rest of Middle East & Africa
  - 9.6.9.1. Rest of Middle East & Africa: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.6.9.2. Rest of Middle East & Africa: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.6.9.3. Rest of Middle East & Africa: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.6.9.4. Rest of Middle East & Africa: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
9.7. Herceptin Biosimilars Market - Latin America
- 9.7.1. Latin America: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
- 9.7.2. Latin America: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
- 9.7.3. Latin America: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
- 9.7.4. Latin America: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.5. Herceptin Biosimilars Market - Mexico
  - 9.7.5.1. Mexico: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.7.5.2. Mexico: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.7.5.3. Mexico: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.7.5.4. Mexico: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.6. Herceptin Biosimilars Market - Brazil
  - 9.7.6.1. Brazil: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.7.6.2. Brazil: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.7.6.3. Brazil: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.7.6.4. Brazil: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.7. Herceptin Biosimilars Market - Argentina
  - 9.7.7.1. Argentina: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.7.7.2. Argentina: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.7.7.3. Argentina: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.7.7.4. Argentina: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.8. Herceptin Biosimilars Market - Rest of Latin America
  - 9.7.8.1. Rest of Latin America: Herceptin Biosimilars Market, by Application, 2020-2034 (USD Million)
  - 9.7.8.2. Rest of Latin America: Herceptin Biosimilars Market, by Dosage, 2020-2034 (USD Million)
  - 9.7.8.3. Rest of Latin America: Herceptin Biosimilars Market, by End-Users, 2020-2034 (USD Million)
  - 9.7.8.4. Rest of Latin America: Herceptin Biosimilars Market, by Distribution Channel, 2020-2034 (USD Million)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. Amgen Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Biocon Biologics Limited
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Celltrion Healthcare Co., Ltd.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Innovent Biologics, Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Mylan Pharmaceuticals Inc.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Novartis AG
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Pfizer Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Samsung Bioepis Co., Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Shanghai Henlius Biotech, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Teva Pharmaceutical Industries Ltd.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development